Protective immunity induced by CpG ODNs against white spot syndrome virus (WSSV) via intermediation of virus replication indirectly in Litopenaeus vannamei.
The worldwide shrimp culture is beset with diseases mainly caused by white spot syndrome virus (WSSV) and suffered huge economic losses, which bring out an urgent need to develop the novel strategies to better protect shrimps against WSSV. In the present study, CpG-rich plasmid pUC57-CpG, plasmid pUC57 and PBS were employed to pretreat shrimps comparatively to evaluate the protective effects of CpG ODNs on shrimps against WSSV. The survival rates, WSSV copy numbers, and antiviral associated factors (Dicer, Argonaute, STAT and ROS) were detected in Litopenaeus vannamei. There were higher survival proportion, lower WSSV copy numbers, and higher mRNA expression of Dicer and STAT in pUC57-CpG-pretreatment shrimps than those in pUC57- and PBS-pretreatment shrimps after WSSV infection. The Argonaute mRNA expression in pUC57-CpG-, pUC57- and PBS-pretreatment shrimps after WSSV infection was significantly higher than that of shrimps post PBS stimulation on the first day. The ROS levels in pUC57-CpG-pretreatment shrimps post secondary stimulation of PBS were significantly higher than those post WSSV infection on the first day. These results together demonstrated that pUC57-CpG induced partial protective immunity in shrimps against WSSV via intermediation of virus replication indirectly and could be used as a potential candidate in the development of therapeutic agents for disease control of WSSV in L. vannamei.
Zhang
Ying
Y
The Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, 7 Nanhai Rd., Qingdao, Shandong 266071, China.
Song
Linsheng
L
Zhao
Jianmin
J
Wang
Lingling
L
Kong
Pengfei
P
Liu
Lin
L
Wang
Mengqiang
M
Qiu
Limei
L
D000818:Animals; D002478:Cells, Cultured; D039642:Eukaryotic Initiation Factors / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D006434:Hemocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D007113:Immunity, Innate / Q000187:drug effects; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage; D033542:Pandalidae / Q000276:immunology*; D017382:Reactive Oxygen Species / Q000276:immunology; D043244:Ribonuclease III / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D050791:STAT Transcription Factors / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000819:agonists; D014777:Virus Diseases / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014779:Virus Replication / Q000187:drug effects; D046848:White spot syndrome virus 1 / Q000472:pathogenicity / Q000502:physiology*
C513533:CpG ODN 2006; C526902:CpG ODN 2216; C527702:CpG ODN 2395; D039642:Eukaryotic Initiation Factors; D009838:Oligodeoxyribonucleotides; D017382:Reactive Oxygen Species; D050791:STAT Transcription Factors; D051217:Toll-Like Receptor 9; D043244:Ribonuclease III